Cyclezyme AB (XSAT:CYCLE) EBIT per Share: kr-0.80 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:CYCLE Cyclezyme AB XSAT:CYCLE
8 GF Score
Price kr26.20
! 3 Warning Signs
View Full Analysis

What is Cyclezyme AB EBIT per Share?

Cyclezyme AB XSAT:CYCLE -1.87% 8 EBIT per Share is kr-0.80 as of Mar. 2026. GuruFocus rates XSAT:CYCLE with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 1,338 Chemicals companies, Cyclezyme AB ranks worse than 56.5% on this metric.

Cyclezyme AB's EBIT per Share for the three months ended in Mar. 2026 was kr-0.32. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.80.

During the past 3 years, the average EBIT per Share Growth Rate was -6.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Cyclezyme AB's EBIT per Share or its related term are showing as below:

XSAT:CYCLE' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -148.7   Med: -77.35   Max: -6
Current: -6

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Cyclezyme AB was -6.00% per year. The lowest was -148.70% per year. And the median was -77.35% per year.

XSAT:CYCLE's 3-Year EBIT Growth Rate is ranked worse than
56.5% of 1338 companies
in the Chemicals industry
Industry Median: -1.15 vs XSAT:CYCLE: -6.00

Cyclezyme AB's EBIT for the three months ended in Mar. 2026 was kr-0.83 Mil.

Cyclezyme AB  (XSAT:CYCLE) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Cyclezyme AB EBIT per Share Related Terms

Cyclezyme AB EBIT per Share Historical Data

* Premium members only.

The historical data trend for Cyclezyme AB's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclezyme AB EBIT per Share Chart

Cyclezyme AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial -0.07 -0.54 -2.61 -0.97 -0.65

Cyclezyme AB Quarterly Data
Dec20 Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.28 -0.17 -0.03 -0.32
XSAT:CYCLE
8GF Score
Cyclezyme AB XSAT:CYCLE
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyclezyme AB EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Cyclezyme AB's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.538/2.372
=-0.65

Cyclezyme AB's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.825/2.590
=-0.32

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of kr-0.80 mean?
Cyclezyme AB (XSAT:CYCLE) has a EBIT per Share of kr-0.80 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cyclezyme AB and its competitors. According to the industry distribution chart, Cyclezyme AB ranks #756 out of 1338 companies in the Chemicals industry, placing it in the top 56.5%.
Is Cyclezyme AB's EBIT per Share too high?
Cyclezyme AB's current EBIT per Share is kr-0.80. Based on the distribution chart, Cyclezyme AB ranks #756 out of 1338 companies in the Chemicals industry, which is below the industry midpoint. Overall, Cyclezyme AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Cyclezyme AB's EBIT per Share compare to LIN and SHW?
According to the Chemicals industry distribution chart, Cyclezyme AB ranks #756 out of 1338 companies for EBIT per Share. This places Cyclezyme AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Chemicals company?
A good EBIT per Share depends on the Chemicals industry context. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cyclezyme AB and its competitors. Cyclezyme AB's current EBIT per Share is kr-0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclezyme AB stock overvalued right now?
Cyclezyme AB (XSAT:CYCLE) has a current EBIT per Share of kr-0.80. The current EBIT per Share is kr-0.80. Cyclezyme AB's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Cyclezyme AB (XSAT:CYCLE), the current EBIT per Share is kr-0.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyclezyme AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Cyclezyme AB is a Sweden-based company that has developed an enzymatic platform focused on producing enzymes for green biochemical processes. This platform utilizes biotechnological methods to identify and improve enzymes capable of converting e.g. PET-based plastic materials for new building blocks. The company enables careful experiments and analyses of the behavior of different enzymes in the breakdown of e.g. PET material. The company refines its enzymes and also optimizes the processes for plastic recycling by combining experimental data with data analysis.
8GF Score

Get the complete analysis for XSAT:CYCLE

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr26.20
Price